This study showed that SCLC-I was the most sensitive to immune checkpoint blockade, SCLC-A was the most sensitive to BCL2 inhibitors, SCLC-N was the most sensitive to Aurora kinase inhibitors (overall, more effective in those SCLC with increased MYCL expression) (67), and SCLC-P was the most sensitive to PARP inhibitors, thus suggesting different classes of drugs for different specific subtypes. The gene discussed is BCL2; the disease is small cell lung carcinoma.